focus -WSS

focus

author：hotspot 2025-08-19 15:02:18 - browse：96

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： JPM: CVS says Medicare Advantage patients are impacting profits

focus

entertainment

WSS

A public health expert passes on football's full body collisions for youths

UCB departs biotech trade group BIO

A single drug, study failures leave Anavex with nothing but cash

Living organ donors deserve priority status for transplants

The thinking behind the controversial eating disorder chatbot Tessa

The biotech scorecard for Q1: 17 stock

focus

focus

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Bispecific antibodies are next new thing in cancer immunotherapy

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA approves first new drug developed for postpartum depression

Novavax promises a turnaround & Lilly roils the obesity market

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Medicare proposal to cover medical devices draws a mixed reaction

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Hepatitis C has a cure — but many Americans still lack access to it

Biogen nominates mother of director’s child to replace him on board

entertainment

U.K. sequencing study surfaces new findings about tumor DNA

Timeline: Key moments in fight for gay rights

Millions may soon lose Medicaid when they don't have to

Altering the blood type of lungs raises potential for universal organs for transplants

Videos point to link between seizures and unexplained toddler deaths

Timeline: Key moments in fight for gay rights

hotspot

focus

entertainment

focus